Evaluation of an Alternative Schedule for CRLX101 Alone in Combination With Bevacizumab and in Combination With mFOLFOX6 in Subjects With Advanced Solid Tumor Malignancies
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 24 Apr 2017
At a glance
- Drugs Camptothecin (Primary) ; Bevacizumab; Fluorouracil; Folic acid; Oxaliplatin
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Cerulean Pharma; NewLink Genetics Corporation
- 18 Apr 2017 Planned End Date changed from 1 Jan 2017 to 1 Dec 2017.
- 18 Apr 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Oct 2017.
- 18 Apr 2017 Status changed from recruiting to active, no longer recruiting.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History